News and Press Releases
MediMab Biotherapeutics opens bespoke laboratory facilities, created by Kadans Science Partner, at Abingdon Science Park, UK
New CL2 wet lab purpose-built facilities delivered by Kadans Science Partner will support MediMab Biotherapeutics to identify first-in-class immuno-oncology drugs that can actively target a range of advanced and solid...
Category: Biotechnology, Manufacturing and Packing, Pharmaceutical
Posted: June 6, 2024
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumours in a Clinical Update Presented at ASCO 2024
An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacy SYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 5, 2024
VALANX Biotech Announces Promising Results in First In-Vivo Study of Novel Protein Conjugate Therapy
Study demonstrates pre-clinical efficacy of lead programme VLX101 in treating autoimmune disease 5 June 2024 - Klosterneuburg, Austria - VALANX Biotech, a biotech company developing novel technology for site-specific protein...
Category:
Posted: June 5, 2024
VALANX Biotech Gmbh, Plöcking 1, IST Park Building, 3400 Klosterneuburg, Austria
FDA and CluePoints Sign New 3 Year Cooperative Research and Development Agreement to Assess Data Quality using Statistical Modelling and Machine Learning
FDA extends its use of CluePoints to include AI/ML within an automated system to assess data quality in multicenter clinical trials 5 June 2024 -- Pennsylvania, US -- CluePoints, providers...
Category: Biotechnology, Pharmaceutical
Posted: June 5, 2024
Sartorius Opens New Center of Excellence for Bioanalytics in Ann Arbor
Manufacturing of instruments, consumables and reagents for cell and protein analysis Consolidation of existing sites and functions in Ann Arbor Overall investment of around $100m. 5 June 2024 -- Michigan,...
Category: BioManufacturing, Manufacturing and Packing, Pharmaceutical
Posted: June 5, 2024
Sartorius Corporation, Otto-Brenner-Straße 20, 37079 Goettingen, Germany
Fortrea Completes Divestiture of Endpoint Clinical and Patient Access Businesses to Arsenal Capital Partners
4 June 2024 -- North Carolina, US -- Fortrea a leading global contract research organisation (CRO), today announced it has completed the divestiture of assets relating to its Enabling Services segment,...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 4, 2024
Kindeva Drug Delivery Expands Loughborough, UK, Facilities at Charnwood Campus to Support Growth of Green Propellant Commercialisation
4 June 2024 -- Loughborough, UK; Minnesota, US; and Missouri, US -- Leading global drug-device combination product CDMO Kindeva Drug Delivery today announced the expansion of their Loughborough, UK, facilities...
Category: BioManufacturing, Drug Delivery, Manufacturing and Packing, Pharmaceutical
Posted: June 4, 2024
CARVYKTI▼ (ciltacabtagene autoleucel; cilta-cel) significantly improved progression-free survival and deepened responses versus two standard therapies for patients with functional high-risk multiple myeloma
73% reduction in risk of disease progression or death seen with cilta-cel in the CARTITUDE-4 study in a subset of patients who had early relapse after initial multiple myeloma therapy...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 4, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Sphere Fluidics launches Cyto-CellectPLUS to accelerate cell line development workflows
4 June 2024 - Cambridge, UK - Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the launch of Cyto-CellectPLUS. In conjunction with...
Category: Biotechnology, Drug Discovery
Posted: June 4, 2024
The Jonas Webb Building, Babraham Research Campus, Babraham, Cambridge CB22 3AT, United Kingdom
Annogen Announces Research Collaboration with Orchard Therapeutics for the Development of CNS-cell Specific Promoters
Annogen to develop immune cell-specific human promoters for certain Orchard pre-clinical programmes 4 June 2024 -- Amsterdam, The Netherlands -- Annogen, a company with expertise in bespoke promoter design and...
Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: June 4, 2024
Kite’s TECARTUS (Brexucabtagene Autoelucel) Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia
After more than four years of follow-up in the pivotal ZUMA-3 study, median overall survival was 26 months and four-year overall survival rate was 40% at 48 months Survival benefit...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024
Encouraging New Data Presented on Kite’s YESCARTA (Axicabtagene Ciloleucel) for Relapsed/Refractory Central Nervous System Lymphoma
At median follow-up of 24.2 months, no apparent additional risks of adverse events related to axicabtagene ciloleucel were seen Findings also suggest efficacy trend with median progression-free survival and durability...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024
TECVAYLI▼ (teclistamab) shows sustained deep and durable responses in patients with relapsed or refractory multiple myeloma
New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched to biweekly dosing Separate analyses from the MajesTEC-1 and OPTec...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
First participant dosed in research study investigating the effects of BPL-003, a novel formulation of 5-MeO-DMT, on the human brain
The study is the first of its kind to assess the effects of 5-MeO-DMT in the human brain and will investigate the neurophysiological effects of BPL-003, Beckley Psytech’s novel synthetic...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024
Gerresheimer to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group – Strategic reset of Moulded Glass business
Strategic acquisition: Complementary product portfolio and broad footprint with production sites in Europe Gerresheimer underpins leading market position as a full-service provider for the pharmaceutical and biotech industries Higher profitability...
Category: Logistics, Manufacturing and Packing
Posted: June 3, 2024
